D. Boral Capital analyst Jason Kolbert downgraded Cero Therapeutics (CERO) to Hold from Buy with no price target Q3 preliminary results highlight capital structure headwinds and the company is delaying its Form 10-Q filing while finalizing accounting related to recent equity transactions, the firm noted as it moved to the sidelines.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CERO: